Beyond the Drip: The State of Immunoglobulin Therapy with Luba Sobolevsky, President & CEO of IgNS

In this episode of Beyond the Drip, Luba Sobolevsky, President & CEO, of the Immunoglobulin National Society (IgNS) joins co-hosts Jon Love, Brian O’Sullivan, Pamela McIntyre, and Brandon Carpenter to discuss the current state of immunoglobulin therapy, and the challenges emerging as demand continues to grow.

Key Takeaways

Immunoglobulin therapy continues to grow, with more than 70 clinical indications and additional uses under investigation. The shift toward home care, ambulatory infusion centers, and other alternate sites is accelerating faster than many providers can adapt. Ig therapy is highly complex. Providers need specialized training, clinical competency, operational protocols, and appropriate accreditation to deliver it safely. Payer policies and step-therapy requirements can create unnecessary barriers, particularly when patients are required to try IVIG before receiving SCIG. Better communication between payers, providers, clinicians, manufacturers, and patient advocates is essential to improving access and reducing inappropriate denials. Patient-satisfaction scores alone do not provide a complete picture of care. Providers should also measure adverse reactions, quality of life, treatment continuity, and clinical outcomes. AI can improve data analysis and administrative efficiency, but relying on it to make coverage decisions without individualized human review could put patients at risk. IgNS is helping the industry establish stronger standards, measure clinical competency, educate providers, and keep patient safety at the center of continued growth.

Guest Speaker:

Luba Sobolevsky, Pharm.D., IgCP®, President | CEO at Immunoglobulin National Society

Dr. Luba Sobolevsky is the President and Chief Executive Officer of the Immunoglobulin National Society (IgNS), the central, standards-setting healthcare organization in the field of Ig therapy and biologics. Dr. Sobolevsky has over 25 years of diverse leadership experience across the healthcare field, including clinical practice, education, and pharmaceutical industry. She oversees IgNS’ strategic initiatives and the development of comprehensive programs and resources that promote best clinical practices and optimal patient outcomes. She is responsible for expanding and improving interdisciplinary and industry-wide collaboration and alliances. Dr. Sobolevsky leads IgNS’ Patient 360 division, dedicated to patient advocacy, education and outcomes research. She has been actively engaged in rese